Fibrosis/Cancer Start-up Seeded By Celgene Begins To Take Shape
This article was originally published in The Pink Sheet Daily
Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.
You may also be interested in...
It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.
A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.
The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.